Lithium in Treatment and Prophylaxis of Affective and Schizoaffective Disorders

  • B. Müller-Oerlinghausen
  • K. Thies
  • J. Volk


Interest in the treatment and prophylaxis of schizoaffective patients with lithium salts seems to be related to two different aspects: First, there is an ongoing search for optimized therapeutic strategies, which always implies the question: Is it possible to replace neuroleptics, or to reduce their dosage in such patients in order to attenuate the risk of extrapyramidal motoric side effects (EPMS)? This is an important issue, since some authors have recently suggested that the risk of neuroleptic-induced EPMS may be particularly high in patients with affective psychosis (Kane 1988, Nasrallah et al. 1988, Waddington and Joussef 1988). Second, it is hoped or presumed that the response or nonresponse to lithium salts would provide a decisive a argument in favor of or against the classification of schizoaffective psychoses among the group of affective disorders (Goodnick and Meltzer 1984, Taylor 1986).


Affective Disorder Bipolar Patient Schizoaffective Disorder Lithium Treatment Lithium Salt 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alexander PE, van Kammen DP, Bunney WE (1979) Antipsychotic effects of lithium in schizophrenia. Am J Psychiatry 136: 283–287PubMedGoogle Scholar
  2. AMP (Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie) (1971) Das AMP-System. Manual zur Dokumentation psychiatrischer Befunde. Springer, Berlin Heidelberg New YorkGoogle Scholar
  3. Angst J, Weis P, Grof P, Baastrup PC, Schou M (1970) Lithium prophylaxis in recurrent affective disorders. Br J Psychiatry 116: 604–614PubMedCrossRefGoogle Scholar
  4. Bobon D (1983) Foreign adaptations of the AMDP-system. Mod Probl Pharmacopsychiatry 20: 19–34PubMedGoogle Scholar
  5. Braden W, Fink EB, Qualls CB, Ho CK, Samuels WO (1982) Lithium and chlorpromazine in psychotic inpatients. Psychiatry Res 7: 69–81PubMedCrossRefGoogle Scholar
  6. Carmen JS, Bigelow LB, Wyatt RJ (1981) Lithium combined with neuroleptics in chronic schizophrenia and schizo-affective patients. J Clin Psychiatry 42: 124–128Google Scholar
  7. Delva NJ, Letemendia FJJ (1982) Lithium treatment in schizophrenia and schizoaffective disorders. Br J Psychiatry 141: 387–400PubMedCrossRefGoogle Scholar
  8. Donaldson SR, Gelenberg AJ, Baldessarini RJ (1983) The pharmacologic treatment of schizophrenia: a progress report. Schizophr Bull 9: 504–524PubMedGoogle Scholar
  9. Garver DL, Hirschowitz J, Fleishmann R, Djuric PE (1984) Lithium response and psychoses: a double-blind, placebo-controlled study. Psychiatry Res 12: 57–68PubMedCrossRefGoogle Scholar
  10. Goodnick PJ, Meltzer HY (1984) Treatment of schizoaffective disorders. Schizophr Bull 10 (1): 30–48PubMedGoogle Scholar
  11. Hofmann G, Kremser M, Katschnig H, Scheiber V (1970) Prophylaktische Lithiumtherapie bei manisch-depressivem Krankheitsgeschehen und bei Legierungspsychosen. Int Pharmacopsychiatry 4: 187–193Google Scholar
  12. Kane JM (1988) The role of neuroleptics in manic-depressive illness. J Clin Psychiatry 49 [Suppl]: 12–14PubMedGoogle Scholar
  13. Küfferle B, Lenz G (1983) Classification and course of schizo-affective psychoses. Follow-up of patients treated with lithium. Psychiatria Clin 16: 169–177Google Scholar
  14. Lenz G, Wolf R (1986) Prophylaxe der schizoaffektiven Psychosen. In: Müller-Oerlinghausen B, Greil W (eds) Die Lithiumtherapie — Nutzen, Risiken, Alternativen. Springer, Berlin Heidelberg New York Tokyo, pp 164–172Google Scholar
  15. Maj M (1984) Effectiveness of lithium prophylaxis is schizoaffective psychoses: application of a polydiagnostic approach. Acta Psychiatr Scand 70: 228–234PubMedCrossRefGoogle Scholar
  16. Maj M (1988), Lithium prophylaxis of schizoaffective disorders: a prospective study. J Affective Disord 14: 129–135CrossRefGoogle Scholar
  17. Mattes JA, Nayak D (1984) Lithium vs. fluphenazine for prophylaxis in mainly schizophrenic schizo-affectives. Biol Psychiatry 19 (3): 445–449PubMedGoogle Scholar
  18. Müller-Oerlinghausen B (1988) Mental functioning. In: Johnson FN (ed) Depression and mania — modern lithium therapy. IRL Press. Oxford, pp 246–252Google Scholar
  19. Nasrallah HA, Churchill CM, Hamdan-Allan GA (1988) Higher frequency of neurolepticinduced dystonia in mania than in schizophrenia. Am J Psychiatry 145: 1455–56PubMedGoogle Scholar
  20. Perris C (1978) Morbidity — suppressive effect of lithium carbonate in cycloid psychosis. Arch Gen Psychiatry 35: 328–331Google Scholar
  21. Perris C, Smigan L (1983) The use of lithium in the long-term morbidity-suppressive treatment of cycloid and schizoaffective psychoses. 7th World Congress of Psychiatry. Pharmacopsychiatry 3: 375–380Google Scholar
  22. Prakash R (1985) Lithium-responsive schizophrenia: case reports. J Clin Psychiatry 46: 141–142PubMedGoogle Scholar
  23. Rosenthal NE, Rosenthal LN, Stallone F, Dunner DL, Fieve RR (1980) Toward the validation of RDC schizoaffective disorder. Arch Gen Psychiatry 37: 804–810PubMedGoogle Scholar
  24. Sautter F, Garver D (1985) Familial differences in lithium-responsive vs. lithium nonrespon-sive psychoses. J Psychiatr Res 19: 1–8PubMedCrossRefGoogle Scholar
  25. Shalev A, Hermesh H, Munitz H (1987) Severe akathisia causing neuroleptic failure: an indication for lithium therapy in schizophrenia? Acta Psychiatr Scand 76: 715–718PubMedCrossRefGoogle Scholar
  26. Small JG, Kellams JJ, Milstein V, Moore J (1975) A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. Am J Psychiatry 132: 1315–1317PubMedGoogle Scholar
  27. Smulevitch AB, Zavidovskaya GI, Igonin AL, Mikhailova NM (1974) The effectiveness of lithium in affective and schizoaffective psychoses. Br J Psychiatry 125: 65–72PubMedCrossRefGoogle Scholar
  28. Spitzer RL, Endicott J, Robins E (1975) Research diagnostic criteria (RDC) for a selected group of functional disorders, 2nd edn Biometrics Research, New York State Psychiatric Institute, New YorkGoogle Scholar
  29. Taylor MA (1986) The validity of schizoaffective disorders: treatment and prevention studies. In: Marneros A, Tsuang MT (eds) Schizoaffective psychoses. Springer, Berlin Heidelberg New York Tokyo, pp 94–114CrossRefGoogle Scholar
  30. Tress W, Haag H (1979) Vergleichende Erfahrungen mit der rezidivprophylaktischen Lithium-Langzeitmedikation bei schizoaffektiven Psychosen. Nervenarzt 50: 524–526PubMedGoogle Scholar
  31. Varanka TM, Weller RA, Weller EB, Fristad MA (1988) Lithium treatment of manic episodes with psychotic features in prepubertal children. Am J Psychiatry 145: 1557–1559PubMedGoogle Scholar
  32. Waddington JL, Youssef HA (1988) Tardive dyskinesia in bipolar affective disorder: aging, cognitive dysfunction, course of illness, and exposure to neuroleptics and lithium. Am J Psychiatry 145: 613–616PubMedGoogle Scholar
  33. Weizsäcker M, Wöller W, Tegeler J (1984) Lithium in der Behandlung periodisch auftretender katatoner Erregungszustände bei Schizophrenen. Nervenarzt 55: 382–384PubMedGoogle Scholar
  34. Woggon B, Dittrich A (1979) Konstruktion übergeordneter AMP-Skalen: “manisch-depressives” and ‘schizophrenes Syndrom“. Int Pharmacopsychiatry 14: 325–337PubMedGoogle Scholar
  35. Zemlan FP, Hirschowitz J, Sautter FJ, Garver DL (1984a) Impact of lithium therapy on core psychotic symptoms of schizophrenia. Br J Psychiatry 144: 64–69PubMedCrossRefGoogle Scholar
  36. Zemlan FP, Hirschowitz J, Garver DL (1984b) Mood-incongruent vs. mood-congruent psychosis: differential antipsychotic response to lithium therapy. Psychiatry Res 11: 317–328PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • B. Müller-Oerlinghausen
  • K. Thies
  • J. Volk
    • 1
  1. 1.Psychiatrische Klinik, Klinische PsychopharmakologieFreie Universität BerlinBerlin 19Germany

Personalised recommendations